GSK-2849466
Overview of the experimental drug GSK-2849466
GSK-2849466[edit | edit source]
GSK-2849466 is an experimental drug developed by GlaxoSmithKline (GSK) that acts as a potent and selective inhibitor of the enzyme poly (ADP-ribose) polymerase (PARP). This compound is part of a class of drugs known as PARP inhibitors, which are being investigated for their potential use in the treatment of various types of cancer.
Mechanism of Action[edit | edit source]
GSK-2849466 functions by inhibiting the activity of PARP enzymes, which play a crucial role in the repair of DNA single-strand breaks through the base excision repair pathway. By blocking PARP activity, GSK-2849466 prevents the repair of DNA damage in cancer cells, leading to the accumulation of DNA breaks and ultimately causing cell death. This mechanism is particularly effective in cancer cells that are already deficient in other DNA repair pathways, such as those with BRCA1 or BRCA2 mutations.
Clinical Development[edit | edit source]
GSK-2849466 is currently undergoing clinical trials to evaluate its safety and efficacy in patients with various types of cancer, including breast cancer, ovarian cancer, and prostate cancer. The drug is being tested both as a monotherapy and in combination with other anticancer agents to determine its potential benefits in different therapeutic contexts.
Potential Benefits[edit | edit source]
The use of GSK-2849466 as a PARP inhibitor offers several potential benefits in cancer treatment. By specifically targeting cancer cells with defective DNA repair mechanisms, it may provide a more targeted approach to therapy, reducing damage to normal cells and minimizing side effects. Additionally, the combination of GSK-2849466 with other treatments may enhance the overall effectiveness of cancer therapy.
Challenges and Considerations[edit | edit source]
While GSK-2849466 shows promise, there are challenges associated with its development and use. These include the need to identify patients who are most likely to benefit from PARP inhibition, managing potential resistance mechanisms that cancer cells may develop, and addressing any adverse effects that may arise during treatment.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
